AU2008202208C1 - Method and medicament for inhibiting the expression of a defined gene - Google Patents

Abstract

5 The invention relates to a medicament containing at least one double-stranded oligoribonucleotide (dsRNA) designed to inhibit the expression of a target gene. According to the invention, one strand of the dsRNA is at least in part complementary to the target gene.

Description

-1 METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A GIVEN GENE The invention relates to a medicament comprising at least one oligoribonucleotide 5 having a double-stranded structure for inhibiting the expression of a given target gene in mammalian cells, and to use of the oligoribonucleotide for inhibiting expression of a given target gene in a mammalian cell. A method is known from WO 99/32619, which was unpublished at the priority date of 10 the present invention. The known process aims at inhibiting the expression of genes in cells of invertebrates. To this end, the double-stranded oligoribonucleotide must exhibit a sequence which is identical with the target gene and which has a length of at least 50 bases. To achieve efficient inhibition, the identical sequence must be 300 to 1 000 base pairs in length. Such an oligoribonucleotide is complicated to prepare. 15 DE 196 31 919 C2 describes an antisense RNA with specific secondary structures, the antisense RNA being present in the form of a vector encoding it. The antisense RNA takes the form of an RNA molecule which is complementary to regions of the mRNA. Inhibition of the gene expression is caused by binding to these regions. This inhibition 20 can be employed in particular for the diagnosis and/or therapy of diseases, for example tumor diseases or viral infections. - The disadvantage is that the antisense RNA must be introduced into the cell in an amount which is at least as high as the amount of the mRNA. The known antisense methods are not particularly effective. 25 US 5,712,257 discloses a medicament comprising mismatched double-stranded RNA (dsRNA) and bioactive mismatched fragments of dsRNA in the form of a ternary complex together with a surfactant. The dsRNA used for this purpose consists of synthetic nucleic acid single strands without defined base sequence. The single N:\Sydney\CasestPatent\4200042999\P42794.AU.2\Specis\P42794 AU 2 Specification 2009-3-16.doc 16/04/09 2 strands undergo irregular base pairing, also known as "non-Watson-Crick" base pairing, giving rise to mismatched double strands. The known dsRNA is used to inhibit the amplification of retroviruses such as HIV. Amplification of the virus can be inhibited 5 when non-sequence-specific dsRNA is introduced into the cells. This leads to the induction of interferon, which is intended to inhibit viral amplification. The inhibitory effect, or the activity, of this method is poor. It is known from Fire, A. et al., NATURE, Vol. 391, pp. 806 that dsRNA whose one 10 strand is complementary in segments to a nematode gene to be inhibited inhibits the expression of this gene highly efficiently. It is believed that the particular activity of the dsRNA used in nematode cells is not due to the antisense principle but possibly on catalytic properties of the dsRNA, or enzymes induced by it. - Nothing is mentioned in this paper on the activity of specific dsRNA with regard to inhibiting the gene 15 expression, in particular in mammalian and human cells. It would be advantageous if at least preferred embodiments of the present invention were to do away with the disadvantages of the prior art. In particular, it would be advantageous to provide as effective as possible a method, medicament or use for the 20 preparation of a medicament, which method, medicament or use is capable of causing particularly effective inhibition of the expression of a given target gene in a mammalian cell. The present invention provides following items (1) to (40): 25 (1) A medicament comprising at least one oligoribonucleotide having a double-stranded structure (dsRNA) for inhibiting the expression of a given target gene in mammalian cells, wherein the dsRNA has 15 to 49 base pairs, wherein one strand of the dsRNA has a region I with not more than 49 successive nucleotide pairs and which is complementary to the target gene, and wherein a complementary region II within the 30 double-stranded structure is formed by two separate RNA single strands 15 to 49 bases 4941801 1 (GHMatters) P42794.AU.2 2A in length, and wherein the target gene is selected from the following group: oncogene, cytokine gene, Id-protein gene, development gene, prion gene. (2) Use of an oligoribonucleotide having a double-stranded structure (dsRNA) for the preparation of a medicament for inhibiting the expression of a given target gene in 5 mammalian cells, wherein the dsRNA has 15 to 49 base pairs, wherein one strand of the dsRNA has a region I with not more than 49 successive nucleotide pairs and which is complementary to the target gene, and wherein a complementary region II within the double-stranded structure is formed by two separate RNA single strands 15 to 49 bases in length, and wherein the target gene is selected from the following group: oncogene, 10 cytokine gene, Id-protein gene, development gene, prion gene. (3) A method for inhibiting the expression of a target gene in a mammalian cell, comprising administering an oligoribonucleotide having a double stranded structure (dsRNA), wherein the dsRNA has 15 to 49 base pairs, wherein one strand of the dsRNA has a region I with not more than 49 successive nucleotide pairs and which is 15 complementary to the target gene, and wherein a complementary region II within the double stranded structure is formed by two separate RNA single strands 15 to 49 bases in length, and wherein the target gene is selected from the following group: oncogene, cytokine gene, Id-protein gene, development gene, prion gene. (4) A medicament, use or method according to any one of items (1) to (3), wherein the 20 dsRNA is enclosed within a micellar structure. (5) A medicament, use, or method according to item (4), wherein the micellar structure is a liposome. (6) A medicament, use or method according to any one of items (1) to (4), wherein the dsRNA is enclosed by natural viral capsids or by chemically or enzymatically produced 25 artificial capsids or structures derived therefrom. (7) A medicament, use or method according to any one of items (1) to (6), wherein segments of the dsRNA are in double-stranded form. (8) A medicament, use or method according to any one of items (1) to (7), wherein the ends of the dsRNA are modified in order to counteract degradation in the cell or 30 dissociation into the single strands.

2B (9) A medicament, use or method according to any one of items (1) to (8), wherein the cohesion of the complementary region II, which is caused by the nucleotide pairs, is increased by at least one further chemical linkage. (10) A medicament, use, or method according to item (9), wherein the cohesion of the 5 complementary region II is increased by at least two further chemical linkages. (11) A medicament, use, or method according to item (9) or (10), wherein the chemical linkage is formed by a covalent or ionic bond, a hydrogen bond, hydrophobic interactions, or by metal-ion coordination. (12) A medicament, use, or method according to item (11), wherein the chemical 10 linkage is formed by van der Waals or stacking interactions. (13) A medicament, use, or method according to any one of items (9) to (12), wherein the chemical linkage is generated at at least one end of the complementary region II. (14) A medicament, use, or method according to item (13), wherein the chemical linkage is generated at both ends of the complementary region II. 15 (15) A medicament, use, or method according to any one of items (9) to (14), wherein the chemical linkage is formed by means of one or more compound groups. (16) A medicament, use, or method according to item (15), wherein the compound groups are poly(oxyphosphinicooxy-1,3-propanediol) and/or polyethylene glycol chains. 20 (17) A medicament, use, or method according to any one of items (9) to (14), wherein the chemical linkage is formed by purine analogs used in the complementary region II in place of purines. (18) A medicament according to any one of items (9) to (14), wherein the chemical linkage is formed by azabenzene units inserted into the complementary region II. 25 (19) A medicament, use, or method according to any one of items (9) to (14), wherein the chemical linkage is formed by branched nucleotide analogs used in the complementary region II in place of nucleotides. (20) A medicament, use, or method according to any one of items (9) to (14), wherein at least one of the following groups is used for generating the chemical linkage: methylene 30 blue; bifunctional groups, N-acetyl-N'-(p-glyoxyl-benzoyl)cystamine; 4-thiouracil; psoralene.

2C (21) A medicament, use, or method according to item (20), wherein the bifunctional group is bis(2-chloroethyl)amine. (22) A medicament according to any one of items (9) to (14), wherein the chemical linkage is formed by thiophosphoryl groups provided at the ends of the double-stranded 5 region. (23) A medicament according to any one of items (9) to (14), wherein the chemical linkages are triple-helix bonds provided at the ends of the double-stranded structure. (24) A medicament, use, or method according to any one of items (1) to (21), wherein at least one 2'-hydroxyl group of the nucleotides of the dsRNA in the complementary 10 region II is replaced by a chemical group. (25) A medicament, use, or method according to item (24), wherein the chemical group is a 2'-amino or a 2'-methyl group. (26) A medicament, use or method according to any one of items (1) to (25), wherein at least one nucleotide in at least one strand of the complementary region II is a "locked 15 nucleotide" with a sugar ring which is chemically modified. (27) A medicament, use, or method according to item (26), wherein the sugar ring is chemically modified by a 2'-0, 4'-C-methylene bridge. (28) A medicament, use or method according to any one of items (1) to (27), wherein the dsRNA is bound to, associated with or surrounded by, at least one viral coat protein 20 which originates from a virus, is derived therefrom or has been prepared synthetically. (29) A medicament, use, or method according to item (28), wherein the coat protein is derived from a polyomavirus. (30) A medicament, use, or method according to item (28) or (29), wherein the coat protein contains a polyomavirus virus protein I (VP 1) and/or virus protein 2 (VP2). 25 (31) A medicament, use, or method according to any one of items (28) to (30), wherein, when a capsid or capsid-type structure is formed from the coat protein, one side faces the interior of the capsid or capsid-type structure. (32) A medicament, use or method according to any one of items (1) to (31), wherein the dsRNA is complementary to the primary or processed RNA transcript of the target 30 gene. 4 41AA1 1 MHMAttArI P47794 AUI 2D (33) A medicament, use or method according to any one of items (1) to (32), wherein the mammalian cells are human cells. (34) A medicament according to any one of items (1) or (4) to (33), wherein at least two dsRNAs which differ from each other are contained in the medicament, wherein one 5 strand of each dsRNA is complementary to, in each case, one of at least two different target genes. (35) Use or method according to any one of items (9) to (14), wherein the chemical linkage is formed by azabenzene units introduced into the complementary region II. (36) Use or method according to any one of items (9) to (14), wherein the chemical 10 linkage is formed by thiophosphoryl groups attached to the ends of the double-stranded region. (37) Use or method according to any one of items (9) to (14), wherein the chemical linkage at the ends of the double-stranded region is formed by triple-helix bonds. (38) Use or method according to any one of items (2) to (21) or (24) to (37), wherein at 15 least two dsRNAs which differ from each other are used, wherein one strand of each dsRNA is complementary to, in each case, one of at least two different target genes. (39) Use according to any one of items (2), (4) to (21) or (24) to (38), wherein the medicament is injectable into the bloodstream or into the interstitium of the organism to undergo therapy. 20 (40) Use or method according to any one of items (2) to (21) or (24) to (39), wherein the dsRNA is taken up into bacteria or microorganisms. In accordance with the present invention, the region I which is complementary to the target gene exhibits not more than 49 successive nucleotide pairs. 25 AgA1801, 1 (rHMatl-1 PA2794 AU : -3 Provided in accordance with the invention are an oligoribonucleotide. or a vector encoding- therefore At least segments of the oligoribonucleotide exhibit a defined nucleotide sequence. The defined segment may be 5 limited to the complementary region I. However, it is also possible that all of the double-stranded oligoribonucleotide exhibits a defined nucleotide sequence. 10 Surprisingly, it has emerged that an effective inhibition of the expression of the target gene can be achieved even when the complementary region I is not more than 49 base pairs in length. The procedure of providing such oligoribonucleotides is less 15 complicated. In particular, dsRNA with a length of over 50 nucleotide pairs induces certain cellular mechanisms, for example the dsRNA-dependent protein 20 kinase or the 2-5A system, in mammalian and human cells. This leads to the disappearance of the interference effect mediated by the dsRNA which exhibits a defined sequence. As a consequence, protein biosynthesis in the cell is blocked. The present 25 invention overcomes this disadvantage in particular. Furthermore, the uptake of dsRNA with short chain lengths into the cell or into the nucleus is facilitated markedly over longer-chain dsRNAs. 30 It has proved advantageous for the dsRNA or the vector to be present packaged into micellar structures, preferably in liposomes. The dsRNA or the vector can likewise be enclosed in viral natural capsids or in 35 chemically or enzymatically produced artificial capsids or structures derived therefrom. - The abovementioned features make it possible to introduce the dsRNA or the vector into given target cells.

-4 The dsRNA has 15 to 49, base pairs. Thus, the dsRNA can be longer than the region I, which is complementary to the target gene. The complementary region I can be located at the terminus or inserted into the dsRNA. Such dsRNA or a vector provided for coding the same can be produced synthetically or enzymatically by customary methods. 5 The gene to be inhibited is expediently expressed in eukaryotic cells. The target gene is selected from the following group: oncogene, cytokin gene, Id protein gene, development gene, prion gene. It can also be expressed in pathogenic organisms, preferably in plasmodia. It can be part of a virus or viroid which is preferably 10 pathogenic to humans. - The method proposed makes it possible to produce compositions for the therapy of genetically determined diseases, for example cancer, viral diseases or Alzheimer's disease. The virus or viroid can also be a virus or viroid which is pathogenic to animals. 1s In some embodiments, segments of the dsRNA are designed as double-stranded. A region II which is complementary within the double-stranded structure is formed by two separate RNA single strands. 20 The ends of the dsRNA can be modified to counteract degradation in the cell or dissociation into the single strands. Dissociation takes place in particular when low concentrations or short chain lengths are used. To inhibit dissociation in a particularly effective fashion, the cohesion of the complementary region II, 25 4941801_1 (GHMatters) P42794.AU.2 -5 which is caused by the nucleotide pairs, can be increased by at least one, preferably two, further chemical linkage(s). - A dsRNA whose dissociation is reduced exhibits greater stability to enzymatic and chemical degradation in the cell or in the organism. 5 The complementary region II can be formed by auto complementary regions of an RNA hairpin loop, in particular when using a vector according to the invention. To afford protection from degradation, it is expedient for the nucleotide to be chemically modified in the loop region between the double-stranded structure. 10 The chemical linkage is expediently formed by a covalent or ionic bond, a hydrogen bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal-ion coordination. In an especially advantageous aspect, it can be formed at at least one, preferably both, end(s) of the complementary region II. 15 It has furthermore proved to be advantageous for the chemical linkage to be formed by one or more linkage groups, the linkage groups preferably being poly(oxyhosphinicooxy- 1,3-propanediol) and/or polyethylene glycol chains. The chemical linkage can also be formed by purine analogs used in place of purines in the complementary regions II. It is also advantageous for the chemical linkage to be 20 formed by azabenzene units introduced into the complementary regions II. Moreover, it can be formed by branched nucleotide analogs used in place of nucleotides in the complementary regions II. It has proved expedient to use at least one of the following groups for generating the 25 chemical linkage: methylene blue; bifunctional groups, preferably N:\Sydney\Cases\Patent\42000-42999\P42794.AU.2\Specis\P 42 7 94

AU.

2 Specification 2009-3-16.doc 16/04/09 -6 bis (2-chloroethyl )amine; N-acetyl-N'- (p-glyoxyl benzoyl)cystamine; 4 -thiouracil; psoralene. The chemical linkage can furthermore be formed by thiophosphoryl groups provided at the ends of the 5 double-stranded region. The chemical linkage at the ends of the double-stranded region is preferably formed by triple-helix bonds. The chemical linkage can expediently be induced by 10 ultraviolet light. The nucleotides of the dsRNA can be modified. This counteracts the activation, in the cell, of a double stranded-RNA-dependent protein kinase, PKR. 15 Advantageously, at least one 2 '-hydroxyl group of the nucleotides of the dsRNA in the complementary region II is replaced by a chemical group, preferably a 2 '-amino or a 2 '-methyl group. At least one nucleotide in at least one strand of the complementary region II can 20 also be a locked nucleotide with a sugar ring which is chemically modified, preferably by a 2'-0, 4'-C methylene bridge. Advantageously, several nucleotides are locked nucleotides. 25 A further especially advantageous embodiment provides that the dsRNA or the vector is bound to, associated with or surrounded by, at least one viral coat protein which originates from a virus, is derived therefrom or has been prepared synthetically. The coat protein can 30 be derived from polyomavirus. The coat protein can contain the polyomavirus virus protein 1 (VPl) and/or virus protein 2 (VP2) . The use of such coat proteins is known from, for example, DE 196 18 797 Al, whose disclosure is herewith incorporated. - The 35 abovementioned features considerably facilitate the introduction of the dsRNA or of the vector into the cell.

When a capsid or capsid-type structure is formed from the coat protein, one side preferably faces the interior of the capsid or capsid-type structure. The construct formed is particularly stable. 5 The dsRNA can be complementary to the primary or processed RNA transcript of the target gene. - The cell can be a human cell. At least two dsRNAs which differ from each other or at least one vector encoding them can be introduced into the cell, where at least segments of one strand of each dsRNA 10 are complementary to in each case one of at least two different target genes. This makes it possible simultaneously to inhibit the expression of at least two different target genes. In order to suppress, in the cell, the expression of a double-stranded-RNA dependent protein kinase, PKR, one of the target genes is advantageously the PKR gene. This allows effective suppression of the PKR activity in the cell. 15 The invention provides a medicament comprising at least one oligoribonucleotide having a double-stranded structure (dsRNA) for inhibiting the expression of a given target gene in mammalian cells, wherein one strand of the dsRNA has a region I with not more than 49 successive nucleotide pairs and which is complementary to the target 20 gene, and wherein a complementary region II within the double-stranded structure is formed by two separate RNA single strands, wherein the target gene is selected from the following group: oncogene, cytokine gene, Id-protein gene, development gene, prion gene.] 25 Surprisingly, it has emerged that such a dsRNA is suitable as medicament for inhibiting the expression of a given gene in mammalian cells. In comparison with the use of single-stranded oligoribonucleotides, the inhibition is already caused at concentrations which are lower by at least one order of magnitude. The medicament according to the invention is highly effective. Lesser side effects can be expected. 30 N:\Sydney\Cases\Patent\4200( 42999\P42794.AU.2\Specis\P42794.AU 2 Specifcation 2009-3-16 doc 16/04/09 - 8 Described herein is a medicament with at least one vector for coding at least one oligoribonucleotide with double-stranded structure (dsRNA) for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to the target gene. 5 The medicament proposed exhibits the abovementioned advantages. By using a vector, in particular production costs can be reduced. The complementary region I has not more than 49 successive nucleotide pairs. Surprisingly, it has emerged that an effective inhibition of the expression of the target 10 gene can be achieved even when the complementary region I is not more than 49 base pairs in length. The procedure of providing such oligoribonucleotides is less complicated. The invention provides use of an oligoribonucleotide having a double-stranded structure 15 (dsRNA) for the preparation of a medicament for inhibiting the expression of a given target gene in mammalian cells, wherein one strand of the dsRNA has a region I with not more than 49 successive nucleotide pairs and which is complementary to the target gene, and wherein a complementary region II within the double-stranded structure is formed by two separate RNA single strands, wherein the target gene is selected from 20 the following group: oncogene, cytokine gene, Id-protein gene, development gene, prion gene. Surprisingly, such a dsRNA is suitable for preparing a medicament for inhibiting the expression of a given gene. Compared with the use of single-stranded 25 oligoribonucleotides, the inhibition is already caused at concentrations which are lower by one order of magnitude when using dsRNA. The use according to the invention thus makes possible the preparation of particularly effective medicaments. Described herein is the use of a vector for coding at least one oligoribonucleotide with 30 double-stranded structure (dsRNA) for preparing a medicament for inhibiting the expression of a given target gene, where one strand of the dsRNA has a region I where at least segments are complementary to this target gene. - The use of a vector makes possible a particularly effective gene therapy. N:\Sydney\Cases\Patent\42000-42999\P42794.AU.2\Specis\P4 2 7 94.AU- 2 Specification 2009-3-16.doc 16/D4/09 -9 With regard to advantageous embodiments of the medicament and of the use, reference is made to the description of the above features. 5 Use examples of the invention are illustrated in greater detail hereinbelow with reference to the figures, in which: 10 Fig. 1 shows the schematic representation of a plasmid for the in vitro transcription with T7- and SP6-polymerase, Fig. 2 shows RNA following electrophoresis on an 8% 15 polyacrylamide gel and staining with ethidium bromide, Fig. 3 shows a representation of radioactive RNA transcripts following electrophoresis on an 8% 20 polyacrylamide gel with 7 M urea by means of an instant imager, and Figs. 4a - e show Texas Red and YFP fluorescence in murine fibroblasts. 25 Use example 1: The inhibition of transcription was detected by means of sequence homologous dsRNA in an in vitro transcription system with a nuclear extract from human 30 HeLa cells. . The DNA template for this experiment was plasmid pCMV1200 which had been linearized by means of BanHI. Generation of the template plasmids: 35 The plasmid shown in fig. 1 was constructed for use in the. enzymatic synthesis of the dsRNA. To this end, a polymerase chain reaction (PCR) with the "positive control DNA" of the HelaScribe* Nuclear Extract in vitro transcription kit by Promega, Madison, USA, as - 10 DNA template was first carried out. One of the primers used contained the sequence of an EcoRI cleavage site and of the T7 RNA polymerase promoter as shown in sequence listing No. 1. The other primer contained the 5 sequence of a BamHI cleavage site and of the SP6 RNA polymerase promoter as shown in sequence listing No. 2. In addition, the two primers had, at the 3' ends, regions which were identical with or complementary to the DNA template. The PCR was carried out by means of 10 the "Taq PCR Core Kits" by Qiagen, Hilden, Germany, following the manufacturer's instructions. 1.5 mM MgCl 2 , in each case 200 AM dNTP, in each case 0.5 AM primer, 2.5 U Tag DNA polymerase and approximately 100 ng of "positive control DNA" were employed as 15 template in PCR buffer in a volume of 100 jil. After initial denaturation of the template DNA by heating for 5 minutes at 94 0 C, amplification was carried out in 30 cycles of denaturation for in each case 60 seconds at 940C, annealing for 60 seconds- at 50C below the 20 calculated melting point of the primers and polymerization for 1.5-2 minutes at 720C. After a final polymerization of 5 minutes at 720C, 5 Al of the reaction were analyzed by agarose-gel electrophoresis. The length of the DNA fragment amplified thus was 25 400 base pairs, 340 base pairs corresponding to the "positive control DNA". The PCR product was purified, hydrolyzed with EcoRI and BarnHI and, after repurification, employed in the ligation together with a pUC18 vector which had also been hydrolyzed by EcoRI 30 and BamHI. E. coli XLl-blue was then transformed. The plasmid obtained (pCMV5) carries a DNA fragment whose 5' end is flanked by the T7 promoter and whose 3' end is flanked by the SP6 promoter. By linearizing the plasmid with BamHI, it can be employed in vitro with 35 the T7-RNA polymerase for the run-off transcription of a single-stranded RNA which is 340 nucleotides in length and shown in sequence listing No. 3. If the plasmid is linearized with EcoRI, it can be employed for the run-off transcription with SP6 RNA polymerase, - 11 giving rise to the complementary strand. In accordance with the method outlined hereinabove, an RNA 23 nucleotides in length was also synthesized. To this end, a DNA shown in sequence listing No. 4 was ligated 5 with the pUC18 vector via the EcoRI and BamHI cleavage sites. Plasmid pCMV1200 was constructed as DNA template for the in-vitro transcription with HeLa nuclear extract. 10 To this end, a 1 191 bp EcoRI/BamHI fragment of the positive control DNA contained in the HeLaScribe* Nuclear Extract in vitro transcription kit was amplified by means of PCR. The amplified fragment encompasses the 828 bp "immediate early" CMV promoter 15 and a 363 bp transcribable DNA fragment. The PCR product was ligated to the vector pGEM-T via "T-overhang" ligation. A BamHI cleavage site is located at the 5' end of the fragment. The plasmid was linearized by hydrolysis with BamHI and used as 20 template in the run-off transcription. In-vitro transcription of the complementary single strands: pCMV5 plasmid DNA was linearized with EcoRI or BamHI. 25 It was used as DNA template for an in-vitro transcription of the complementary RNA single strands with SP6 and T7 RNA polymerase, respectively. The "Riboprobe in vitro Transcription" system by Promega, Madison, USA, was employed for this purpose. Following 30 the manufacturer's instructions, 2 gg of linearized plasmid DNA were incubated in 100 gl of transcription buffer and 40 U T7 or SP6 RNA polymerase for 5-6 hours at 370C. The DNA template was subsequently degraded by addition of 2.5 gl of RNase-free DNase RQl and 35 incubation for 30 minutes at 370C. The transcription reaction was made up to 300 gl with H 2 0 and purified by phenol extraction. The RNA was precipitated by addition of 150 gl of 7 M ammonium acatate [sic] and 1 125 gl of - 12 ethanol and stored at -650C until used for the hybridization. Generation of the RNA double strands: 5 For the hybridization, 500 gl of the single-stranded RNA which had been stored in ethanol and precipitated were spun down. The resulting pellet was dried and taken up in 30 gl of PIPES buffer, pH 6.4 in the presence of 80% formamide, 400 mM NaCl and 1 mM EDTA. 10 In each case 15 1 l of the complementary single strands were combined and heated for 10 minutes at 85OC. The reactions were subsequently incubated overnight at 50 0 C and cooled to room temperature. 15 Only approximately equimolar amounts of the two single strands were employed in the hybridization. This is why the dsRNA preparations contained single-stranded RNA (ssRNA) as contaminant. In order to remove these ssRNA contaminants, the reactions were treated, after 20 hybridization, with the single-strand-specific ribonucleases bovine pancreatic RNase A and Aspergillus oryzae RNase Tl. RNase A is an endoribonuclease which is specific for pyrimidines. RNase Tl is an endoribonuclease which preferentially cleaves at the 3' 25 side of guanosines. dsRNA is no substrate for these ribonucleases. For the RNase treatment, the reactions in 300 gl of Tris, pH 7.4, 300 mM NaCl and 5 mM EDTA were treated with 1.2 4 of RNaseA at a concentration of 10 mg/ml and 2 gl of RNaseTl at a concentration of 30 290 ug/ml. The reactions were incubated for 1.5 hours at 30 0 C. Thereupon, the RNases were denatured by addition of 5 gl of proteinase K at a concentration of 20 mg/ml and 10 4 of 20% SDS and incubation for 30 minutes at 37 0 C. The dsRNA was purified by phenol 35 extraction and precipitated with ethanol. To verify the completeness of the RNase digestion, two control reactions were treated with ssRNA analogously to the hybridization reactions.

- 13 The dried pellet was taken up in 15 4 of TE buffer, pH 6.5, and subjected to native polyacrylamide gel electrophoresis on an 8% gel. The acrylamide gel was subsequently stained in an ethidium bromide solution 5 and washed in a water bath. Fig. 2 shows the RNA which had been visualized in a UV transilluminator. The sense RNA which had been applied to lane 1 and the antisense RNA which had been applied to lane 2 showed a different migration behavior under the chosen conditions than the 10 dsRNA of the hybridization reaction which had been applied to lane 3. The RNase-treated sense RNA and antisense RNA which had been applied to lanes 4 and 5, respectively, produced no visible band. This shows that the single-stranded RNAs had been degraded completely. 15 The RNase-treated dsRNA of the hybridization reaction which had been applied to lane 6 is resistant to RNase treatment. The band which migrates faster in the native gel in comparison with the dsRNA applied to lane 3 results from dsRNA which is free from ssRNA. In 20 addition to the dominant main band, weaker bands which migrate faster are observed after the RNase treatment. In-vitro transcription test with human nuclear extract: Using the HeLaScribe* Nuclear Extract in vitro 25 transcription kit by Promega, Madison, USA, the transcription efficiency of the abovementioned DNA fragment which is present in plasmid pCMV1200 and homologous to the "positive control DNA" was determined in the presence of the dsRNA (dsRNA-CMV5) with sequence 30 homology. Also, the effect of the dsRNA without sequence homology, which corresponds to the yellow fluorescent protein (YFP) gene (dsRNA-YRP), was studied. This dsRNA had been generated analogously to the dsRNA with sequence homology. The sequence of a 35 strand of this dsRNA can be found in sequence listing No. 5. Plasmid pCMV1200 was used as template for the run-off transcription. It carries the "immediate early" cytomegalovirus promoter which is recognized by the eukaryotic RNA polymerase II, and a transcribable DNA - 14 fragment. Transcription was carried out by means of the HeLa nuclear extract, which contains all the proteins which are necessary for transcription. By addition of

[-

3 2 P]rGTP to the transcription reaction, radiolabeled 5 transcript was obtained. The [-_ 32 P]rGTP used had a specific activity of 400 Ci/mmol, 10 mCi/ml. 3 mM MgCl 2 , in each case 400 gM rATP, rCTP, rUTP, 16 gM rGTP, 0.4 gM [- -P]rGTP and depending on the experiment 1 fmol of linearized plasmid DNA and various amounts of 10 dsRNA in transcription buffer were employed per reaction. Each batch was made up to a volume of 8.5 4l with H 2 0. The reactions were mixed carefully. To start the transcription, 4 U HeLa nuclear extract in a volume of 4 gl were added and incubated for 60 minutes at 15 300C. The reaction was stopped by addition of 87.5 gul of quench mix which had been warmed to 30 0 C. To remove the proteins, the reactions were treated with 100 jil of phenol/chloroform/isoamyl alcohol (25:24:1 v/v/v) saturated with TE buffer, pH 5.0, and the reactions 20 were mixed vigorously for 1 minute. For phase separation, the reactions were spun for approximately 1 minute at 12 000 rpm and the top phase was transferred into a fresh reaction vessel. Each reaction was treated with 250 yl of ethanol. The reactions were 25 mixed thoroughly and incubated for at least 15 minutes on dry ice/methanol. To precipitate the RNA, the reactions were spun for 20 minutes at 12 000 rpm and 401C. The supernatant was discarded. The pellet was dried in vacuo for 15 minutes and resuspended in 10 Al 30 of H 2 0. Each reaction was treated with 10 gl of denaturing loading buffer. The free GTP was separated from the transcript formed by means of denaturing polyacrylamide gel electrophoresis on an 8% gel with 7 M urea. The RNA transcripts formed upon transcription 35 with HeLa nuclear extract, in denaturing loading buffer, were heated for 10 minutes at 900C and 10 4l aliquots were applied immediately to the freshly washed pockets. The electrophoresis was run at 40 mA. The amount of the radioactive ssRNA formed upon - 15 transcription was analyzed after electrophoresis with the aid of an Instant Imager. Fig. 3 shows the radioactive RNA from a representative 5 test, shown by means of the Instant Imager. Samples obtained from the following transcription reactions were applied: Lane 1: without template DNA, without dsRNA; 10 Lane 1: 50 ng of template DNA, without dsRNA; Lane 3: 50 ng of template DNA, 0.5 gg of dsRNA YFP; Lane 4: 50 ng of template DNA, 1.5 gg of dsRNA YFP; Lane 5: 50 ng of template DNA, 3 gg of dsRNA YFP; Lane 6: 50 ng of template DNA, 5 gg of dsRNA YFP; 15 Lane 7: without template DNA, 1.5 dsRNA YFP; Lane 8: 50 ng of template DNA, without dsRNA; Lane 9: 50 ng of template DNA, 0.5 gg of dsRNA CMV5; Lane 10: 50 ng of template DNA, 1.5 gg of dsRNA CMV5; Lane 11: 50 ng of template DNA, 3 gg of dsRNA CMV5; 20 Lane 12: 50 ng of template DNA, 5 gg of dsRNA CMV5; It emerged that the amount of transcript was reduced markedly in the presence of dsRNA with sequence homology in comparison with the control reaction 25 without dsRNA and with the reactions with dsRNA YFP without sequence homology. The positive control in lane 2 shows that radioactive transcript was formed upon the in-vitro transcription with HeLa nuclear extract. The reaction is used for comparison with the transcription 30 reactions which had been incubated in the presence of dsRNA. Lanes 3 to 6 show that the addition of non sequentially-specific dsRNA YFP had no effect on the amount of transcript formed. Lanes 9 to 12 show that the addition of an amount of between 1.5 and 3 gg of 35 sequentially-specific dsRNA CMV5 leads to a reduction in the amount of transcript formed. In order to exclude that the effects observed are based not on the dsRNA but on any contamination which might have been carried along accidentally during the preparation of the dsRNA, - 16 a further control was carried out. Single-stranded RNA was transcribed as described above and subsequently subjected to the RNase treatment. It was demonstrated by means of native polyacrylamide gel electrophoresis 5 that the ssRNA had been degraded completely. This reaction was subjected to phenol extraction and ethanol precipitation and subsequently taken up in PE buffer, as were the hybridization reactions. This gave a sample which contained no RNA but had been treated with the 10 same enzymes and buffers as the dsRNA. Lane 8 shows that the addition of this sample had no effect on transcription. The reduction of the transcript upon addition of sequence-specific dsRNA can therefore be ascribed unequivocally to the dsRNA itself. The 15 reduction of the amount of transcript of a gene in the presence of dsRNA in a human transcription system indicates an inhibition of the expression of the gene in question. This effect can be attributed to a novel mechanism caused by the dsRNA. 20 Use example 2: The test system used for these in-vivo experiments was the murine fibroblast cell line NIH3T3, ATCC CRL-1658. The YFP gene was introduced into the nuclei with the 25 aid of microinjection. Expression of YFP was studied under the effect of simultaneously cotransfected dsRNA with sequence homology. This dsRNA YFP shows homology with the 5'-region of the YFP gene over a length of 315 bp. The nucleotide sequence of a strand of the 30 dsRNA YRP is shown in sequence listing No. 5. Evaluation under the fluorescence microscope was carried out 3 hours after injection with reference to the greenish-yellow fluorescence of the YFP formed. 35 Construction of the template plasmid, and preparation of the dsRNA: A plasmid was constructed following the same principle as described in use example 1 to act as template for the production of the YFP dsRNA by means of T7 and SP6 - 17 in-vitro transcription. Using the primer EcoT7_YFP as shown in sequence listing No. 6 and BamrSP6_YFP as shown in sequence listing No. 7, the desired gene fragment was amplified by PCR and used analogously to 5 the above description for preparing the dsRNA. The dsRNA YFP obtained is identical to the dsRNA used in use example 1 as non-sequence-specific control. A dsRNA linked chemically at the 3' end of the RNA as 10 shown in sequence listing No. 8 to the 5' end of the complementary RNA via a C18 linker group was prepared (L-dsRNA) . To this end, synthons modified by disulfide bridges were used. The 3'-terminal synthon is bound to the solid support via the 3' carbon with an aliphatic 15 linker group via a disulfide bridge. In the 5'-terminal synthon of the complementary oligoribonucleotide which is complementary to the 3'-terminal synthon of the one oligoribonucleotide, the 5'-trityl protecting group is bound via a further aliphatic linker and a disulfide 20 bridge. Following synthesis of the two single strands, removal of the protecting groups and hybridization of the complementary oligoribonucleotides, the thiol groups which form are brought into spatial vicinity. The single strands are linked to each other by 25 oxidation via their aliphatic linkers and a disulfide bridge. This is followed by purification with the aid of HPLC. Preparation of the cell cultures: 30 The cells were incubated in DMEM supplemented with 4.5 g/l glucose, 10% fetal bovine serum in culture dishes at 37 0 C under a 7.5% CO 2 atmosphere and passaged before reaching confluence. The cells were detached with trypsin/EDTA. To prepare for microinjection, the 35 cells were transferred into Petri dishes and incubated further until microcolonies formed.

- 18 Microinjection: For the microinjection, the culture dishes were removed from the incubator for approximately 10 minutes. Approximately 50 nuclei were injected singly per 5 reaction within a marked area using the AIS microinjection system from Carl Zeiss, Gbttingen, Germany. The cells were subsequently incubated for three more hours. For the microinjection, borosilicate glass capillaries from Hilgenberg GmbH, Malsfeld, 10 Germany, with a diameter of less than 0.5 ym at the tip were prepared. The microinjection was carried out using a micromanipulator from Narishige Scientific Instrument Lab., Tokyo, Japan. The injection time was 0.8 seconds and the pressure was approximately 100 hPa. The 15 transfection was carried out using the plasmid pCDNA YFP, which contains an approximately 800 bp BamHI/EcoRI fragment with the YFP gene in vector pcDNA3. The samples injected into the nuclei contained 0.01 ugg/l of pCDNA-YFP and Texas Red coupled to dextran-70000 in 20 14 mM NaCl, 3 mM KCl, 10 mM KPO 4 [sic], ph 7.5. Approximately 100 pl of RNA with a concentration of 1 gM or, in the case of the L-dsRNA, 375 4M were additionally added. 25 The cells were studied under a fluorescence microscope with excitation with the light of the excitation wavelength of Texas Red, 568 nm, or of YFP, 488 nm. Individual cells were documented by means of a digital camers. Figures 4a-e show the result for NIH3T3 cells. 30 In the cells shown in Fig. 4a, sense-YFP-ssRNA has been injected, in Fig. 4b antisense-YFP-ssRNA, in Fig. 4c dsRNA-YFP, in Fig. 4d no RNA and in Fig. 4e L-dsRNA. The field on the left shows in each case the 35 fluorescence of cells with excitation at 568 nm. The fluorescence of the same cells at an excitation of 488 nm is seen on the right. The Texas Red fluorescence of all the cells shown demonstrates that the injection solution had been applied successfully into the nuclei - 19 and that cells with successful hits were still alive after three hours. Dead cells no longer showed Texas Red fluorescence. 5 The right fields of each of figures 4a and 4b show that YFP expression was not visibly inhibited when the single-stranded RNA was injected into the nuclei. The right field of Fig. 4c shows cells whose YFP fluorescence was no longer detectable after the 10 injection of dsRNA-YFP. Fig. 4d shows cells into which no RNA had been injected, as control. The cell shown in fig. 4e shows YFP fluorescence which can no longer be detected owing to the injection of the L-dsRNA which shows regions with sequence homology to the YFP gene. 15 This result demonstrates that even shorter dsRNAs can be used for specifically inhibiting gene expression in mammals when the double strands are stabilized by chemically linking the single strands.

20 Literatur: Asanuma, H., Ito, T., Yoshida, T., Liang, X. & Komiyama, M. (1999). Photoregulation der Bildung und Dissoziation ei 5 nes DNA-Duplexes durch cis-trans-Isomerisierung einer Azobenzoleinheit- .Angew. Chem. 111, 2547-2549. Azhayeva, E., Azhayev, A., Auriola, S., Tengvall, U.,.Urtti, A. & Lbnnberg, H. (1997). Inhibitory properties of double 10 helix forming.circular oligonucleotides. Nucl. Acids Res. 25, 4954-4961. Castelli, J., Wood, K.A. & Youle, R.J. (1998). The 2-5A system in viral infection and apoptosis. Biomed. Pharmacother. 15 52, 386-390. Dolinnaya,. N.G., Blumenfeld, M., Merenkova, I., Oretskaya, T.S.., Krynetskaya, N. F.. Ivanovskaya, M.G.,Vasseur, M. & Shabarova Z.A. (1993). Oligonucleotide circularization 20 by template-directed chemical ligation. Nucl. Acids Res. 21, 5403-5407. Expert-Bezancon, A., Milet, M. & Carbon, P'. (1983). Precise localization of several covalent RNA-RNA cross-link in 25 Escherichia coli 16S RNA. Eur. J. Biochem. 136, 267-274. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. & Mello, C.C. (1998) . Potent and specific genetic inter ference by double-stranded RNA in Caenorhabditis elegans. 30 Nature 391, 806-811.

21 Gao, H., Yang, M., Patel, R. & Cook, A.F. (1995). Circulaiza tion of oligonucleotides by disulfide bridge formation. Nucl. Acids Res. 23, 2025-2029. 5 Gryaznov, S.M4. &Letsinger,. R.L. (1993). Template controlled coupling and recombination of oligonucleotide blocks con taining thiophosphoryl groups. Nucl. Acids Res. 21, 1403 1408. 10 Kaufman, R.J. (1999). Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: A new role for an old actor. Proc. Natl. Acad. Sci. USA 96, 11693-11695 Lipson, S.E. & Hearst, J.E. (1988). Psoralen cross-linking of 15 ribosomal RNA. In Methods in Enzymology Anonymous pp. 330-341. Liu, Z-R., Sargueil, 5 & Smith, C.W. (1998). Detection of a novel ATP-dependent cross-linked protein at the 5' splice 20 site-Ul small nuclear RNA duplex .by methylene blue mediated photo-cross-linking. Mol. Cell. Biol. 18, 6910 .6920. Micura, R. (1999). Cyclic oligoribonucleotides (RNA) by solid 25 phase synthesis. Chem. Eur. J. 5, 2077-2082. Skripkin, E., Isel, C., Marquet, R., Ehresmann, B. & Ehres mann, C. (1996). Psoralen crosslinking between human im munodeficiency virus type 1 RNA and primer tRNA 3 yS. Nucl. 30 Acids Res. 24, 509-514.

22 Wang, S. & Kool, E.T. (1994). Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a Compa rison with circular'DNAs. Nucl. Acids Res. 22, 2326-2333. 5 Wang, Z. & Rana, T.M. (1996). RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking. Biochem. 35, 6491-6499. Watkins, K.P. & Agabian, N. (1991). In vivo UV cross-linking 10 of U snRNAs that paticipate in trypanosome trans splicing. Genes & Development 5, 1859-1869. Wengel, J. (1999). Synthesis of 3'-C- and 4'-C-branched oligo deoxynucleotides and the development of locked nucleic 15 acid (LNA). Acc. Chem. Res. 32, 301-310 Zwieb, C., Ross, A., Rinke J., Meinke, M. & Brimacombe, R. (1978). Evidence for RNA-RNA cross-link formation in Escherichia coli ribosomes. Nucl. Acids Res." 5, 2705 20 2720.

- 22A In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, 5 the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention. It is to be understood that a reference herein to a prior art document does not constitute 10 an admission that the document forms part of the common general knowledge in the art in Australia or any other country. 505285_1 (GHMatters) 3/08/09

Claims (40)

1. A medicament comprising at least one oligoribonucleotide having a double-stranded structure (dsRNA) for inhibiting the expression of a given target gene 5 in mammalian cells, wherein the dsRNA has 15 to 49 base pairs, wherein one strand of the dsRNA has a region I with not more than 49 successive nucleotide pairs and which is complementary to the target gene, and wherein a complementary region II within the double-stranded structure is formed by two separate RNA single strands 15 to 49 bases in length, and wherein the target gene is selected from the following group: oncogene, 10 cytokine gene, Id-protein gene, development gene, prion gene.

2. Use of an oligoribonucleotide having a double-stranded structure (dsRNA) for the preparation of a medicament for inhibiting the expression of a given target gene in mammalian cells, wherein the dsRNA has 15 to 49 base pairs, wherein is one strand of the dsRNA has a region I with not more than 49 successive nucleotide pairs and which is complementary to the target gene, and wherein a complementary region II within the double-stranded structure is formed by two separate RNA single strands 15 to 49 bases in length, and wherein the target gene is selected from the following group: oncogene, cytokine gene, Id-protein gene, development gene, prion 20 gene.

3. A method for inhibiting the expression of a target gene in a mammalian cell, comprising introducing into the cell an oligoribonucleotide having a double stranded structure (dsRNA), wherein the dsRNA has 15 to 49 base pairs, wherein one 25 strand of the dsRNA has a region I with not more than 49 successive nucleotide pairs and which is complementary to the target gene, and wherein a complementary region II within the double stranded structure is formed by two separate RNA single strands 15 to 49 bases in length, and wherein the target gene is selected from the following group: oncogene, cytokine gene, Id-protein gene, development gene, prion gene. 30 24

4. A medicament, use, or method according to any one of claims I to 3, wherein the dsRNA is enclosed within a micellar structure.

5. A medicament, use, or method according to claim 4, wherein the 5 micellar structure is a liposome.

6. A medicament, use, or method according to any one of claims 1 to 4, wherein the dsRNA is enclosed by natural viral capsids or by chemically or enzymatically produced artificial capsids or structures derived therefrom. 10

7. A medicament, use, or method according to any one of claims 1 to 6, wherein segments of the dsRNA are in double-stranded form.

8. A medicament, use, or method according to any one of claims 1 to 7, 15 wherein the ends of the dsRNA are modified in order to counteract degradation in the cell or dissociation into the single strands.

9. A medicament, use, or method according to any one of claims 1 to 8, wherein the cohesion of the complementary region II, which is caused by the nucleotide 20 pairs, is increased by at least one further chemical linkage.

10. A medicament, use, or method according to claim 9, wherein the cohesion of the complementary region II is increased by at least two further chemical linkages. 25

11. A medicament, use, or method according to claim 9 or 10, wherein the chemical linkage is formed by a covalent or ionic bond, a hydrogen bond, hydrophobic interactions, or by metal-ion coordination. 30

12. A medicament, use, or method according to claim 11, wherein the chemical linkage is formed by van der Waals or stacking interactions. AQIAn I I (WMntI.rm PA,7QA AU 25

13. A medicament, use, or method according to any one of claims 9 to 12, wherein the chemical linkage is generated at at least one end of the complementary region II. 5

14. A medicament, use, or method according to claim 13, wherein the chemical linkage is generated at both ends of the complementary region II.

15. A medicament, use, or method according to any one of claims 9 to 14, wherein the chemical linkage is formed by means of one or more compound groups. 10

16. A medicament, use, or method according to claim 15, wherein the compound groups are poly(oxyphosphinicooxy-1,3-propanediol) and/or polyethylene glycol chains. 15

17. A medicament, use, or method according to any one of claims 9 to 14, wherein the chemical linkage is formed by purine analogs used in the complementary region II in place of purines.

18. A medicament according to any one of claims 9 to 14, wherein the 20 chemical linkage is formed by azabenzene units inserted into the complementary region II.

19. A medicament, use, or method according to any one of claims 9 to 14, wherein the chemical linkage is formed by branched nucleotide analogs used in the 25 complementary region II in place of nucleotides.

20. A medicament, use, or method according to any one of claims 9 to 14, wherein at least one of the following groups is used for generating the chemical linkage: methylene blue; bifunctional groups, N-acetyl-N'-(p-glyoxyl-benzoyl)cystamine; 30 4-thiouracil; psoralene. 26

21. A medicament, use, or method according to claim 20, wherein the bifunctional group is bis(2-chloroethyl)amine.

22. A medicament according to any one of claims 9 to 14, wherein the 5 chemical linkage is formed by thiophosphoryl groups provided at the ends of the double-stranded region.

23. A medicament according to any one of claims 9 to 14, wherein the chemical linkages are triple-helix bonds provided at the ends of the double-stranded 10 structure.

24. A medicament, use, or method according to any one of claims I to 21, wherein at least one 2'-hydroxyl group of the nucleotides of the dsRNA in the complementary region II is replaced by a chemical group. 15

25. A medicament, use, or method according to claim 24, wherein the chemical group is a 2'-amino or a 2'-methyl group.

26. A medicament, use, or method according to any one of claims 1 to 25, 20 wherein at least one nucleotide in at least one strand of the complementary region II is a "locked nucleotide" with a sugar ring which is chemically modified.

27. A medicament, use, or method according to claim 26, wherein the sugar ring is chemically modified by a 2'-0, 4'-C-methylene bridge. 25

28. A medicament, use, or method according to any one of claims 1 to 27, wherein the dsRNA is bound to, associated with or surrounded by, at least one viral coat protein which originates from a virus, is derived therefrom or has been prepared synthetically. 30

29. A medicament, use, or method according to claim 28, wherein the coat protein is derived from a polyomavirus. 27

30. A medicament, use, or method according to claim 28 or 29, wherein the coat protein contains a polyomavirus virus protein 1 (VP 1) and/or virus protein 2 (VP2). 5

31. A medicament, use, or method according to any one of claims 28 to 30, wherein, when a capsid or capsid-type structure is formed from the coat protein, one side faces the interior of the capsid or capsid-type structure.

32. A medicament, use, or method according to any one of claims 1 to 31, 10 wherein the dsRNA is complementary to the primary or processed RNA transcript of the target gene.

33. A medicament, use, or method according to any one of claims 1 to 32, wherein the mammalian cells are human cells. 15

34. A medicament according to any one of claims I or 4 to 33, wherein at least two dsRNAs which differ from each other are contained in the medicament, wherein one strand of each dsRNA is complementary to, in each case, one of at least two different target genes. 20

35. Use or method according to any one of claims 9 to 14, wherein the chemical linkage is formed by azabenzene units introduced into the complementary region II. 25

36. Use or method according to any one of claims 9 to 14, wherein the chemical linkage is formed by thiophosphoryl groups attached to the ends of the double-stranded region.

' 37. Use or method according to any one of claims 9 to 14, wherein the 30 chemical linkage at the ends of the double-stranded region is formed by triple-helix bonds. 28

38. Use or method according to any one of claims 2 to 21 or 24 to 37, wherein at least two dsRNAs which differ from each other are used, wherein one strand of each dsRNA is complementary to, in each case, one of at least two different target genes. 5

39. Use according to any one of claims 2, 4 to 21 or 24 to 38, wherein the medicament is injectable into the bloodstream or into the interstitium of the organism to undergo therapy. 10

40. Use or method according to any one of claims 2 to 21 or 24 to 39, wherein the dsRNA is taken up into bacteria or microorganisms. 1.5